CTLA4 and melanoma: Susok et al. published a small cohort of 49 stage III and IV melanoma patients and reported an increase in SV after 3 months of follow-up, particularly with the use of anti-CTLA-4 and anti-CTLA-4/anti-PD-1 regimens [14].